ALKERMES | ALKS - 营业费用

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.96B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	营业费用	更改		日
AbbVie	USD 10.27B		1000K	2026-06
Acadia Pharmaceuticals	USD 270.12M		2.55M	2026-06
ALKERMES	USD 1.81B		57.02M	2026-06
Amgen	USD 11.69B		6.9B	2026-06
Biogen	USD 2.98B		1.02B	2026-06
BioMarin Pharmaceutical	USD 6.32B		5.69B	2026-06
Bristol-Myers Squibb	USD 22.32B		2.25B	2026-06
Coherus Biosciences	USD 51.83M		2.48M	2025-12
Eli Lilly	USD 10.52B		496M	2026-06
Gilead Sciences	USD 3.95B		19.57B	2026-06
Heron Therapeutics	USD 40.55M		1.46M	2025-12
Ionis Pharmaceuticals	USD 370.24M		6.24M	2026-06
J&J	USD 17.83B		388M	2026-06
Malin Corporation	EUR 1.1M		400K	2024-12
Merck	USD 15.77B		2.4B	2026-06
Minerva Neurosciences	USD 4.52M		155.46K	2024-12
Nektar Therapeutics	USD 49.12M		8.22M	2026-03
Neurocrine Biosciences	USD 739.1M		139.2M	2026-06
Otsuka Holdings	JPY 561.64B		49.51B	2026-06
Ovoca Bio	EUR 173K		990K	2025-12
Pfizer	USD 85.19B		4.91B	2026-06
Regeneron Pharmaceuticals	USD 31.71B		287.8M	2026-06
Vertex Pharmaceuticals	USD 2.07B		217.1M	2026-06